IGM Biosciences Statistics
Total Valuation
IGM Biosciences has a market cap or net worth of $78.85 million. The enterprise value is -$25.46 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, before market open.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IGM Biosciences has 60.19 million shares outstanding. The number of shares has increased by 53.11% in one year.
| Current Share Class | 34.80M |
| Shares Outstanding | 60.19M |
| Shares Change (YoY) | +53.11% |
| Shares Change (QoQ) | +101.45% |
| Owned by Insiders (%) | 2.54% |
| Owned by Institutions (%) | 13.65% |
| Float | 11.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.83 |
| Forward PS | 4.94 |
| PB Ratio | 0.78 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.66
| Current Ratio | 17.66 |
| Quick Ratio | 17.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -47.82% and return on invested capital (ROIC) is 2.91%.
| Return on Equity (ROE) | -47.82% |
| Return on Assets (ROA) | 1.73% |
| Return on Invested Capital (ROIC) | 2.91% |
| Return on Capital Employed (ROCE) | 6.07% |
| Revenue Per Employee | $973,490 |
| Profits Per Employee | -$358,289 |
| Employee Count | 149 |
| Asset Turnover | 0.65 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.26% in the last 52 weeks. The beta is 0.48, so IGM Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -88.26% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 4.24 |
| Relative Strength Index (RSI) | 56.48 |
| Average Volume (20 Days) | 569,854 |
Short Selling Information
The latest short interest is 404,560, so 0.67% of the outstanding shares have been sold short.
| Short Interest | 404,560 |
| Short Previous Month | 393,583 |
| Short % of Shares Out | 0.67% |
| Short % of Float | 3.65% |
| Short Ratio (days to cover) | 0.34 |
Income Statement
In the last 12 months, IGM Biosciences had revenue of $145.05 million and -$53.39 million in losses. Loss per share was -$0.58.
| Revenue | 145.05M |
| Gross Profit | 75.47M |
| Operating Income | 6.12M |
| Pretax Income | -236.33M |
| Net Income | -53.39M |
| EBITDA | 13.50M |
| EBIT | 6.12M |
| Loss Per Share | -$0.58 |
Full Income StatementBalance Sheet
The company has $104.31 million in cash and n/a in debt, giving a net cash position of $104.31 million or $1.73 per share.
| Cash & Cash Equivalents | 104.31M |
| Total Debt | n/a |
| Net Cash | 104.31M |
| Net Cash Per Share | $1.73 |
| Equity (Book Value) | 100.93M |
| Book Value Per Share | 1.68 |
| Working Capital | 100.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$156.51 million and capital expenditures -$2.19 million, giving a free cash flow of -$158.70 million.
| Operating Cash Flow | -156.51M |
| Capital Expenditures | -2.19M |
| Free Cash Flow | -158.70M |
| FCF Per Share | -$2.64 |
Full Cash Flow StatementMargins
Gross margin is 52.03%, with operating and profit margins of 4.22% and -36.80%.
| Gross Margin | 52.03% |
| Operating Margin | 4.22% |
| Pretax Margin | -36.80% |
| Profit Margin | -36.80% |
| EBITDA Margin | 9.30% |
| EBIT Margin | 4.22% |
| FCF Margin | n/a |
Dividends & Yields
IGM Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.11% |
| Shareholder Yield | -53.11% |
| Earnings Yield | -67.71% |
| FCF Yield | -201.27% |
Analyst Forecast
The average price target for IGM Biosciences is $6.00, which is 356.27% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.00 |
| Price Target Difference | 356.27% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 2.97% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
